Amonafide (AS1413) |
Cytotoxic |
Topoisomerase II inhibitor |
Antisoma |
III |
Clofarabine |
Cytotoxic |
Purine nucleoside |
Genzyme |
III |
Decitabine |
Cytotoxic |
DNA hypomethylating agent |
Eisai/Johnson & Johnson |
III |
Midostaurin (PKC412) |
Targeted |
Flt-3 tyrosine kinase inhibitor |
Novartis |
III |
PR1 peptide antigen vaccine |
Immunotherapy |
Peptide-based therapeutic vaccine |
The Vaccine Company |
III |
Daunorubicin |
Cytotoxic |
Topoisomerase inhibitor |
Gilead |
III |
Tipifarnib |
Targeted |
Farnesyl transferase inhibitor |
Janssen |
III |
Theralux |
Photodynamic |
Radical formation stimulant |
Kiadis |
III |
Lestaurtinib (CEP-701) |
Targeted |
TKI including Flt-3, TrkA, and JAK2 |
Cephalon |
III |
Belinostat (PXD-101) |
Cytotoxic |
HDAC inhibitor |
Spectrum Pharmaceuticals |
III |
ON 01910.Na |
Cytotoxic |
Cell cycle inhibitor |
Onconova Therapeutics |
II |